Cargando…
Vaccine Preventable Disease Seroprevalence in a Nationwide Assessment of Timor-Leste (VASINA-TL): study protocol for a population-representative cross-sectional serosurvey
INTRODUCTION: Historic disruption in health infrastructure combined with data from a recent vaccine coverage survey suggests there are likely significant immunity gaps to vaccine preventable diseases and high risk of outbreaks in Timor-Leste. Community-based serological surveillance is an important...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201250/ https://www.ncbi.nlm.nih.gov/pubmed/37202138 http://dx.doi.org/10.1136/bmjopen-2022-071381 |
_version_ | 1785045227075010560 |
---|---|
author | Arkell, Paul Sheridan, Sarah L Martins, Nelson Tanesi, Maria Y Gomes, Nelia Amaral, Salvador Oakley, Tessa Solano, Vanessa David, Michael Draper, Anthony D K Sarmento, Nevio da Silva, Endang Alves, Lucsendar Freitas, Carlito Machado, Filipe de Neri Gusmão, Celia da Costa Barreto, Ismael Fancourt, Nicholas S S Macartney, Kristine Yan, Jennifer Francis, Joshua R |
author_facet | Arkell, Paul Sheridan, Sarah L Martins, Nelson Tanesi, Maria Y Gomes, Nelia Amaral, Salvador Oakley, Tessa Solano, Vanessa David, Michael Draper, Anthony D K Sarmento, Nevio da Silva, Endang Alves, Lucsendar Freitas, Carlito Machado, Filipe de Neri Gusmão, Celia da Costa Barreto, Ismael Fancourt, Nicholas S S Macartney, Kristine Yan, Jennifer Francis, Joshua R |
author_sort | Arkell, Paul |
collection | PubMed |
description | INTRODUCTION: Historic disruption in health infrastructure combined with data from a recent vaccine coverage survey suggests there are likely significant immunity gaps to vaccine preventable diseases and high risk of outbreaks in Timor-Leste. Community-based serological surveillance is an important tool to augment understanding of population-level immunity achieved through vaccine coverage and/or derived from prior infection. METHODS AND ANALYSIS: This national population-representative serosurvey will take a three-stage cluster sample and aims to include 5600 individuals above 1 year of age. Serum samples will be collected by phlebotomy and analysed for measles IgG, rubella IgG, SARS-CoV-2 antispike protein IgG, hepatitis B surface antibody and hepatitis B core antigen using commercially available chemiluminescent immunoassays or ELISA. In addition to crude prevalence estimates and to account for differences in Timor-Leste’s age structure, stratified age-standardised prevalence estimates will be calculated, using Asia in 2013 as the standard population. Additionally, this survey will derive a national asset of serum and dried blood spot samples which can be used for further investigation of infectious disease seroepidemiology and/or validation of existing and novel serological assays for infectious diseases. ETHICS AND DISSEMINATION: Ethical approval has been obtained from the Research Ethics and Technical Committee of the Instituto Nacional da Saúde, Timor-Leste and the Human Research Ethics Committee of the Northern Territory Department of Health and Menzies School of Health Research, Australia. Co-designing this study with Timor-Leste’s Ministry-of-Health and other relevant partner organisations will allow immediate translation of findings into public health policy, which may include changes to routine immunisation service delivery and/or plans for supplementary immunisation activities. |
format | Online Article Text |
id | pubmed-10201250 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-102012502023-05-23 Vaccine Preventable Disease Seroprevalence in a Nationwide Assessment of Timor-Leste (VASINA-TL): study protocol for a population-representative cross-sectional serosurvey Arkell, Paul Sheridan, Sarah L Martins, Nelson Tanesi, Maria Y Gomes, Nelia Amaral, Salvador Oakley, Tessa Solano, Vanessa David, Michael Draper, Anthony D K Sarmento, Nevio da Silva, Endang Alves, Lucsendar Freitas, Carlito Machado, Filipe de Neri Gusmão, Celia da Costa Barreto, Ismael Fancourt, Nicholas S S Macartney, Kristine Yan, Jennifer Francis, Joshua R BMJ Open Infectious Diseases INTRODUCTION: Historic disruption in health infrastructure combined with data from a recent vaccine coverage survey suggests there are likely significant immunity gaps to vaccine preventable diseases and high risk of outbreaks in Timor-Leste. Community-based serological surveillance is an important tool to augment understanding of population-level immunity achieved through vaccine coverage and/or derived from prior infection. METHODS AND ANALYSIS: This national population-representative serosurvey will take a three-stage cluster sample and aims to include 5600 individuals above 1 year of age. Serum samples will be collected by phlebotomy and analysed for measles IgG, rubella IgG, SARS-CoV-2 antispike protein IgG, hepatitis B surface antibody and hepatitis B core antigen using commercially available chemiluminescent immunoassays or ELISA. In addition to crude prevalence estimates and to account for differences in Timor-Leste’s age structure, stratified age-standardised prevalence estimates will be calculated, using Asia in 2013 as the standard population. Additionally, this survey will derive a national asset of serum and dried blood spot samples which can be used for further investigation of infectious disease seroepidemiology and/or validation of existing and novel serological assays for infectious diseases. ETHICS AND DISSEMINATION: Ethical approval has been obtained from the Research Ethics and Technical Committee of the Instituto Nacional da Saúde, Timor-Leste and the Human Research Ethics Committee of the Northern Territory Department of Health and Menzies School of Health Research, Australia. Co-designing this study with Timor-Leste’s Ministry-of-Health and other relevant partner organisations will allow immediate translation of findings into public health policy, which may include changes to routine immunisation service delivery and/or plans for supplementary immunisation activities. BMJ Publishing Group 2023-05-18 /pmc/articles/PMC10201250/ /pubmed/37202138 http://dx.doi.org/10.1136/bmjopen-2022-071381 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Infectious Diseases Arkell, Paul Sheridan, Sarah L Martins, Nelson Tanesi, Maria Y Gomes, Nelia Amaral, Salvador Oakley, Tessa Solano, Vanessa David, Michael Draper, Anthony D K Sarmento, Nevio da Silva, Endang Alves, Lucsendar Freitas, Carlito Machado, Filipe de Neri Gusmão, Celia da Costa Barreto, Ismael Fancourt, Nicholas S S Macartney, Kristine Yan, Jennifer Francis, Joshua R Vaccine Preventable Disease Seroprevalence in a Nationwide Assessment of Timor-Leste (VASINA-TL): study protocol for a population-representative cross-sectional serosurvey |
title | Vaccine Preventable Disease Seroprevalence in a Nationwide Assessment of Timor-Leste (VASINA-TL): study protocol for a population-representative cross-sectional serosurvey |
title_full | Vaccine Preventable Disease Seroprevalence in a Nationwide Assessment of Timor-Leste (VASINA-TL): study protocol for a population-representative cross-sectional serosurvey |
title_fullStr | Vaccine Preventable Disease Seroprevalence in a Nationwide Assessment of Timor-Leste (VASINA-TL): study protocol for a population-representative cross-sectional serosurvey |
title_full_unstemmed | Vaccine Preventable Disease Seroprevalence in a Nationwide Assessment of Timor-Leste (VASINA-TL): study protocol for a population-representative cross-sectional serosurvey |
title_short | Vaccine Preventable Disease Seroprevalence in a Nationwide Assessment of Timor-Leste (VASINA-TL): study protocol for a population-representative cross-sectional serosurvey |
title_sort | vaccine preventable disease seroprevalence in a nationwide assessment of timor-leste (vasina-tl): study protocol for a population-representative cross-sectional serosurvey |
topic | Infectious Diseases |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201250/ https://www.ncbi.nlm.nih.gov/pubmed/37202138 http://dx.doi.org/10.1136/bmjopen-2022-071381 |
work_keys_str_mv | AT arkellpaul vaccinepreventablediseaseseroprevalenceinanationwideassessmentoftimorlestevasinatlstudyprotocolforapopulationrepresentativecrosssectionalserosurvey AT sheridansarahl vaccinepreventablediseaseseroprevalenceinanationwideassessmentoftimorlestevasinatlstudyprotocolforapopulationrepresentativecrosssectionalserosurvey AT martinsnelson vaccinepreventablediseaseseroprevalenceinanationwideassessmentoftimorlestevasinatlstudyprotocolforapopulationrepresentativecrosssectionalserosurvey AT tanesimariay vaccinepreventablediseaseseroprevalenceinanationwideassessmentoftimorlestevasinatlstudyprotocolforapopulationrepresentativecrosssectionalserosurvey AT gomesnelia vaccinepreventablediseaseseroprevalenceinanationwideassessmentoftimorlestevasinatlstudyprotocolforapopulationrepresentativecrosssectionalserosurvey AT amaralsalvador vaccinepreventablediseaseseroprevalenceinanationwideassessmentoftimorlestevasinatlstudyprotocolforapopulationrepresentativecrosssectionalserosurvey AT oakleytessa vaccinepreventablediseaseseroprevalenceinanationwideassessmentoftimorlestevasinatlstudyprotocolforapopulationrepresentativecrosssectionalserosurvey AT solanovanessa vaccinepreventablediseaseseroprevalenceinanationwideassessmentoftimorlestevasinatlstudyprotocolforapopulationrepresentativecrosssectionalserosurvey AT davidmichael vaccinepreventablediseaseseroprevalenceinanationwideassessmentoftimorlestevasinatlstudyprotocolforapopulationrepresentativecrosssectionalserosurvey AT draperanthonydk vaccinepreventablediseaseseroprevalenceinanationwideassessmentoftimorlestevasinatlstudyprotocolforapopulationrepresentativecrosssectionalserosurvey AT sarmentonevio vaccinepreventablediseaseseroprevalenceinanationwideassessmentoftimorlestevasinatlstudyprotocolforapopulationrepresentativecrosssectionalserosurvey AT dasilvaendang vaccinepreventablediseaseseroprevalenceinanationwideassessmentoftimorlestevasinatlstudyprotocolforapopulationrepresentativecrosssectionalserosurvey AT alveslucsendar vaccinepreventablediseaseseroprevalenceinanationwideassessmentoftimorlestevasinatlstudyprotocolforapopulationrepresentativecrosssectionalserosurvey AT freitascarlito vaccinepreventablediseaseseroprevalenceinanationwideassessmentoftimorlestevasinatlstudyprotocolforapopulationrepresentativecrosssectionalserosurvey AT machadofilipedeneri vaccinepreventablediseaseseroprevalenceinanationwideassessmentoftimorlestevasinatlstudyprotocolforapopulationrepresentativecrosssectionalserosurvey AT gusmaocelia vaccinepreventablediseaseseroprevalenceinanationwideassessmentoftimorlestevasinatlstudyprotocolforapopulationrepresentativecrosssectionalserosurvey AT dacostabarretoismael vaccinepreventablediseaseseroprevalenceinanationwideassessmentoftimorlestevasinatlstudyprotocolforapopulationrepresentativecrosssectionalserosurvey AT fancourtnicholasss vaccinepreventablediseaseseroprevalenceinanationwideassessmentoftimorlestevasinatlstudyprotocolforapopulationrepresentativecrosssectionalserosurvey AT macartneykristine vaccinepreventablediseaseseroprevalenceinanationwideassessmentoftimorlestevasinatlstudyprotocolforapopulationrepresentativecrosssectionalserosurvey AT yanjennifer vaccinepreventablediseaseseroprevalenceinanationwideassessmentoftimorlestevasinatlstudyprotocolforapopulationrepresentativecrosssectionalserosurvey AT francisjoshuar vaccinepreventablediseaseseroprevalenceinanationwideassessmentoftimorlestevasinatlstudyprotocolforapopulationrepresentativecrosssectionalserosurvey |